A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis ...

Dr Annalisa Morgan previews discussions on disease-modifying therapies, emerging treatments such as CAR T-cell therapy, and ...

Charlotte Wright is living with multiple sclerosis that is leaving her housebound. She fears what disability benefit reforms ...

announced that it is commencing recruitment of 215 patients for a Phase II clinical trial in relapsing-remitting multiple sclerosis (BioMS Medical clinical trials).

also known as relapsing-remitting MS (RRMS). According to the MS Society, in RRMS people have attacks of new and old symptoms, i.e. a relapse. RRMS is the most common type of multiple sclerosis ...

Dr Annalisa Morgan provides ACTRIMS 2025 highlights, including anticipated presentations, quick takeaways, and insights into ...

There are relapsing-remitting and progressive types of MS, but the course is rarely predictable. Researchers still don’t fully understand the cause of MS or why the rate of progression is so ...

When news broke in October that an approved cancer therapy had, for the first time, halted the progress of multiple sclerosis (MS), excitement was tangible among clinicians and patient groups.

A low educational status was associated with longer delays before initiating treatment among relapsing-remitting MS patients ...